Literature DB >> 12187081

A comparison between the soluble transferrin receptor, transferrin saturation and serum ferritin as markers of iron state in hemodialysis patients.

Charles Beerenhout1, Otto Bekers, Jeroen P Kooman, Frank M van der Sande, Karel M L Leunissen.   

Abstract

An adequate iron management is important in the treatment of anemia and in hemodialysis (HD) patients. Serum ferritin and transferrin saturation (TS) may be influenced by the presence of inflammation. Recently, the soluble transferrin receptor (s-TfR) has been advocated as a parameter of iron status in HD patients. The aim of the present study was to assess firstly the relation between serum ferritin, TS, and s-TfR in HD patients and to predict their agreement (assessed by kappa) in the diagnosis of iron deficiency, and, secondly, to assess the influence of inflammation on the relation between the parameters of iron state. Iron deficiency by either marker was respectively defined as ferritin <100 microg/l, TS <20%, or s-TfR >2.4 microg/ml. In the overall group of patients, TS and s-TfR were significantly related (r = -0.38), whereas s-TfR and serum ferritin were not. Both serum ferritin and TS were related to CRP (r = 0.50 and -0.34; p < 0.05), whereas s-TfR was not. The kappa value for agreement between serum ferritin and TS in the diagnosis of iron deficiency was 0.24 (p = 0.07), 0.12 (p = NS) for the agreement between TS and s-TfR and 0 for that between serum ferritin and s-TfR. In patients with CRP levels <or=2 mg/l (n = 16), the relation between parameters of iron state did not improve. Concluding, a large disagreement is observed between ferritin, TS and sTfR as markers of iron deficiency in HD patients, which appears to be only partly explained by the effect of inflammation. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187081     DOI: 10.1159/000064468

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  How should stainable iron in bone marrow films be assessed?

Authors:  D A Hughes; S E Stuart-Smith; B J Bain
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

2.  Comparison of Methods Study between a Photonic Crystal Biosensor and Certified ELISA to Measure Biomarkers of Iron Deficiency in Chronic Kidney Disease Patients.

Authors:  Ross D Peterson; Kenneth R Wilund; Brian T Cunningham; Juan E Andrade
Journal:  Sensors (Basel)       Date:  2017-09-25       Impact factor: 3.576

3.  Non-mercaptalbumin, Oxidized Form of Serum Albumin, Significantly Associated with Renal Function and Anemia in Chronic Kidney Disease Patients.

Authors:  Shinya Nakatani; Keiko Yasukawa; Eiji Ishimura; Ayumi Nakatani; Norikazu Toi; Hideki Uedono; Akihiro Tsuda; Shinsuke Yamada; Hitoshi Ikeda; Katsuhito Mori; Masanori Emoto; Yutaka Yatomi; Masaaki Inaba
Journal:  Sci Rep       Date:  2018-11-14       Impact factor: 4.379

Review 4.  Biomarkers of hypochromia: the contemporary assessment of iron status and erythropoiesis.

Authors:  Eloísa Urrechaga; Luís Borque; Jesús F Escanero
Journal:  Biomed Res Int       Date:  2013-02-28       Impact factor: 3.411

Review 5.  Acute phase reactants as novel predictors of cardiovascular disease.

Authors:  M S Ahmed; A B Jadhav; A Hassan; Qing H Meng
Journal:  ISRN Inflamm       Date:  2012-05-06

6.  Pathogenic Mechanisms Underlying Iron Deficiency and Iron Overload: New Insights for Clinical Application.

Authors:  M J Kotze; D P van Velden; S J van Rensburg; R Erasmus
Journal:  EJIFCC       Date:  2009-08-25

7.  The Iron Status of Sickle Cell Anaemia Patients in Ilorin, North Central Nigeria.

Authors:  Musa A Sani; James O Adewuyi; Abiola S Babatunde; Hannah O Olawumi; Rasaki O Shittu
Journal:  Adv Hematol       Date:  2015-10-15

8.  Serum transferrin predicts end-stage Renal Disease in Type 2 Diabetes Mellitus patients.

Authors:  Lijun Zhao; Yutong Zou; Junlin Zhang; Rui Zhang; Honghong Ren; Lin Li; Ruikun Guo; Jie Zhang; Fang Liu
Journal:  Int J Med Sci       Date:  2020-07-29       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.